1. De Silva DL, Stafford L, Skandarajah AR, et al. Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care. Med J Aust. 2023;218(8):368–373. doi:10.5694/mja2.51906

2. ,De Silva DL, James PA, Mann GB, Lindeman GJ. Universal genetic testing of patients with newly diagnosed breast cancer – ready for prime time? Med J Aust. 2021;215(10):449–453. doi:10.5694/mja2.51317

3. Offin M, De Silva DL, Sauter JL, et al. Multimodality therapy in patients with primary pericardial mesothelioma. J Thorac Oncol. 2022;17(12):1428–1432. doi:10.1016/j.jtho.2022.08.017

4. De Silva DL, Winship I. Is CHEK2 a moderate-risk breast cancer gene or the younger sister of Li-Fraumeni? BMJ Case Rep. 2020;13(9):e236435. doi:10.1136/bcr-2020-236435

5. Li N, Zethoven M, McInerny S, et al. Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing. J Med Genet. 2023;60(2):112–118. doi:10.1136/jmedgenet-2021-108399

6. De Silva DL, Luo J. Clinical approach to utilising liquid biopsies to interrogate suspected acquired resistance to PD-1 blockade. Future Science OA. 2024;10(1). doi:10.2144/fsoa-2023-0010

7. Zettler CM, De Silva DL, Blinder VS, Robson ME, Elkin EB. Cost-effectiveness of adjuvant olaparib for patients with breast cancer and germline BRCA1/2 mutations. JAMA Netw Open. 2024;7(1):e2350067. doi:10.1001/jamanetworkopen.2023.50067

8. De Silva MVC, Dodampahala SH, Wijeratne MDM, et al. Clinicopathological features of premenopausal women over 40 years with dysfunctional uterine bleeding. Sri Lanka J Obstet Gynaecol. 2008;30(Suppl 1):121.

Manuscripts under review

1. Circulating tumour DNA oncogenic driver detection in patients with stage II–III non-small-cell lung cancer using a liquid biopsy platform. Submitted to The Journal of Thoracic and Cardiovascular Surgery.

2. Refining actionable HER2 alterations in lung cancer through next-generation sequencing. Submitted to Clinical Cancer Research.

Posters and presentations

1. San Antonio Breast Cancer Symposium (SABCS) 2021. Mutational assessment of newly diagnosed breast cancer using germline and tumour genomics. doi:10.1158/1538-7445.SABCS21-P3-09-02

2. ASCO Annual Meeting 2022. Cost-effectiveness of adjuvant olaparib for BRCA-mutated early-stage breast cancer. J Clin Oncol. 2022;40(16_suppl):6593. doi:10.1200/JCO.2022.40.16_suppl.6593

3. Pathmanathan S, Matthiesson J, De Silva D, Sabesan S. Perceived barriers to optimal lung cancer care in North Queensland. COSA–IPOS Joint Scientific Meeting 2012. Poster presentation.

4. De Silva DL et al. Combined germline and somatic sequencing in breast cancer confirms pathogenicity of underlying germline mutations and identifies therapeutically vulnerable tumours. COSA–IPOS Joint Scientific Meeting 2023. Oral presentation.

5. De Silva DL et al. Universal germline testing for women with breast cancer in a multidisciplinary setting: impact and benefit. COSA–IPOS Joint Scientific Meeting 2023. Oral presentation.

6. San Antonio Breast Cancer Symposium 2023. Universal germline testing of women with newly diagnosed breast cancer: patient acceptance and impact on clinical management. Accepted poster (SABCS2023_PO1-02).

7. San Antonio Breast Cancer Symposium 2023. Universal whole-genome tumour and germline sequencing of newly diagnosed breast cancer identifies a high proportion of ER-positive BRCA-like tumours. Supervising author.